Intranasal recombinant alfa-2b interferon treatment of naturally occurring common colds.
In a double-blind, placebo-controlled study, patients with naturally occurring common colds of less than or equal to 48 h duration were randomly assigned to receive nasal sprays of recombinant alfa-2b interferon at 10 or 20 MU/day or placebo four times per day for 5 days. The 10-MU (n = 74), 20-MU (...
محفوظ في:
| الحاوية / القاعدة: | Antimicrob Agents Chemother |
|---|---|
| المؤلفون الرئيسيون: | , , |
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
American Society for Microbiology (ASM)
1988
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC172139/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/2834996/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.32.2.224 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|